Swedish mitochondrial medicine firm NeuroVive Pharmaceutical (Nasdaq OMX: NVP) and Yungjin Pharm (KRX: 003520) have entered into a global licensing agreement to develop KL1333 for genetic disorders.
Yungjin, a South Korean firm, is developing the drug to treat orphan mitochondrial conditions. The company has received approval to commence a clinical study which will begin in the coming months.
Yungjin Pharm has granted NeuroVive exclusive global rights to develop and commercialize KL1333 worldwide, except for Korea and Japan, where Yungjin Pharm retains all commercial and marketing rights.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze